NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.55 -0.08 (-12.70 %)
(As of 06/19/2018 06:54 AM ET)
Previous Close$0.63
Today's Range$0.55 - $0.61
52-Week Range$0.43 - $2.89
Volume523,200 shs
Average Volume250,347 shs
Market Capitalization$96.67 million
P/E RatioN/A
Dividend YieldN/A
Matinas BioPharma logoMatinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in the United States. It develops orally delivered therapeutics based on cochleate delivery technology, a proprietary lipid-based drug delivery platform. The company's lead product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B, a broad spectrum anti-fungal drug, which has completed Phase II clinical study for the treatment of fungal infections. Its lead product candidate also includes MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-7,558.92%
Return on Equity-195.09%
Return on Assets-79.34%


Outstanding Shares93,480,000

Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) posted its quarterly earnings results on Thursday, May, 10th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The business earned $0.03 million during the quarter. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. View Matinas BioPharma's Earnings History.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Matinas BioPharma.

What price target have analysts set for MTNB?

2 Wall Street analysts have issued 12 month price targets for Matinas BioPharma's shares. Their predictions range from $4.00 to $9.00. On average, they anticipate Matinas BioPharma's share price to reach $6.50 in the next twelve months. View Analyst Ratings for Matinas BioPharma.

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a increase in short interest in May. As of May 31st, there was short interest totalling 1,724,740 shares, an increase of 0.2% from the May 15th total of 1,721,104 shares. Based on an average daily trading volume, of 162,241 shares, the short-interest ratio is currently 10.6 days. Currently, 2.3% of the shares of the stock are sold short.

Who are some of Matinas BioPharma's key competitors?

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the folowing people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 44)
  • Mr. Dominick M. DiPaolo, Sr. VP of Quality & Regulatory Compliance (Age 42)
  • Mr. Gary Gaglione CPA, VP of Fin. & Accounting and Acting CFO (Age 65)
  • Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 71)

Has Matinas BioPharma been receiving favorable news coverage?

Press coverage about MTNB stock has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Matinas BioPharma earned a news sentiment score of 0.10 on Accern's scale. They also assigned news coverage about the company an impact score of 44.98 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Royal Bank of Canada (0.84%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.

Which institutional investors are buying Matinas BioPharma stock?

MTNB stock was bought by a variety of institutional investors in the last quarter, including Royal Bank of Canada. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.55.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $96.67 million.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.

MarketBeat Community Rating for Matinas BioPharma (MTNB)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.